Citation Impact
Citing Papers
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
2019 StandoutScienceNobel
Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation
2001 StandoutScienceNobel
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
2001 StandoutScienceNobel
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production
2005 StandoutNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways.
2003 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Redox regulation of the hypoxia-inducible factor
2006
Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent
1998
Signal transduction via platelet-derived growth factor receptors
1998
Antiangiogenic Agents Are Effective Inhibitors of Endometriosis
2003
C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation
2001 StandoutNobel
Somatic mosaicism in von Hippel-Lindau disease
2000
The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma
2002
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
2002 StandoutNatureNobel
The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity
1999
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
1999 Standout
Clinical translation of angiogenesis inhibitors
2002 Standout
Role of Immunoglobulin-like Domains 2–4 of the Platelet-derived Growth Factor α-Receptor in Ligand-Receptor Complex Assembly
1998
Rapamycin is an effective inhibitor of human renal cancer metastasis11See Editorial by Sukhatme and Strom, p. 1160.
2003
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Tumor angiogenesis: past, present and the near future
2000
Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function
2000
The Von Hippel-Lindau Protein Interacts with Heteronuclear Ribonucleoprotein A2 and Regulates Its Expression
2001
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
1999 StandoutNatureNobel
Ran-mediated Nuclear Export of the von Hippel-Lindau Tumor Suppressor Protein Occurs Independently of Its Assembly with Cullin-2
2000
Role of Exon 2-encoded β-Domain of the von Hippel-Lindau Tumor Suppressor Protein
2001
The von Hippel–Lindau tumor suppressor protein
2001 StandoutNobel
Homologous Up-regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor in Vitro
1998
MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis
2002
The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing
2003 StandoutNobel
Drosophila von Hippel-Lindau Tumor Suppressor Complex Possesses E3 Ubiquitin Ligase Activity
2000
Requirements for Binding and Signaling of the Kinase Domain Receptor for Vascular Endothelial Growth Factor
1998
Angiogenesis in cancer and other diseases
2000 StandoutNature
The Hallmarks of Cancer
2000 Standout
von Hippel-Lindau Disease
1997 StandoutNobel
The biology of VEGF and its receptors
2003 Standout
Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC
1999
Oncogenes as inducers of tumor angiogenesis
1995
The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix
1998 StandoutNobel
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease
2001
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF
2001
Regulation of angiogenesis by hypoxia: role of the HIF system
2003 StandoutNobel
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
Mapping the Charged Residues in the Second Immunoglobulin-like Domain of the Vascular Endothelial Growth Factor/Placenta Growth Factor Receptor Flt-1 Required for Binding and Structural Stability
1998
Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo
2006 StandoutNobel
Inhibition of Insulin-like Growth Factor-I-mediated Cell Signaling by the von Hippel-Lindau Gene Product in Renal Cancer
2000
Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region
2001
Vascular endothelial growth factor
1996
VEGF and the quest for tumour angiogenesis factors
2002
Characterization of Novel Vascular Endothelial Growth Factor (VEGF) Receptors on Tumor Cells That Bind VEGF165 via Its Exon 7-encoded Domain
1996
Hypoxia and Vascular Endothelial Growth Factor Selectively Up-regulate Angiopoietin-2 in Bovine Microvascular Endothelial Cells
1999
Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis
1995
Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders
2003
Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
2011 StandoutNobel
OncogenicrasFails to Restore anin VivoTumorigenic Phenotype in Embryonic Stem Cells Lacking Vascular Endothelial Growth Factor (VEGF)
1999
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia
2003 Standout
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene
1998
The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
2005 StandoutNobel
Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1
1998
Regional Suppression of Tumor Growth by In Vivo Transfer of a cDNA Encoding a Secreted Form of the Extracellular Domain of the flt-1 Vascular Endothelial Growth Factor Receptor
1998
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
2002 StandoutNobel
The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase
2007 StandoutNobel
Crystal Structure at 1.7 Å Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor
1997
Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor
1996
An Important von Hippel-Lindau Tumor Suppressor Domain Mediates Sp1-Binding and Self-Association
1999
The VHL tumour-suppressor gene paradigm
1998 StandoutNobel
Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre‐eclampsia
1997
Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel‐Lindau gene and hypoxia
2002
VEGFs, receptors and angiogenesis
1999
Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells
2003
Multiple Splice Variants of the Human HIF-3α Locus Are Targets of the von Hippel-Lindau E3 Ubiquitin Ligase Complex
2003
VHL Gene Deletion and Enhanced VEGF Gene Expression Detected in the Stromal Cells of Retinal Angioma
1999
Endogenous Inhibitors of Angiogenesis
2005
Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
2000 StandoutNobel
Transcription-Dependent Nuclear-Cytoplasmic Trafficking Is Required for the Function of the von Hippel-Lindau Tumor Suppressor Protein
1999
Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells
1998
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
2004 Standout
Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex
2000
VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
2000
Role of transforming growth factor-α in von Hippel– Lindau (VHL) −/− clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
2001
Transcription Elongation and Human Disease
1999
Protective Function of von Hippel-Lindau Protein against Impaired Protein Processing in Renal Carcinoma Cells
1999
Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
1997
Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations
2000 StandoutNobel
Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase
1999 StandoutScienceNobel
von Hippel-Lindau Disease
2006 StandoutNobel
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
2002 StandoutNobel
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
1996
Posttranslational hydroxylation of ankyrin repeats in IκB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH)
2006 StandoutNobel
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins
1997
PROLINE HYDROXYLATION AND GENE EXPRESSION
2005 StandoutNobel
The Biology of Vascular Endothelial Growth Factor
1997 Standout
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.
1994
Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis.
2001
Effects of PTK787/ZK222584, a Tyrosine Kinase Inhibitor, on the Growth of a Poorly Differentiated Thyroid Carcinoma: An Animal Study
2003
Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy
2002
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
2019 StandoutNobel
Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
1998
Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen
2008 StandoutNobel
The von Hippel-Lindau Tumor Suppressor Gene
2020
Impact of oncogenes in tumor angiogenesis: Mutant K- ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells
1998
pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation
1998 StandoutNobel
Studying interactions of four proteins in the yeast two-hybrid system: Structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein
1999
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice
1997
Reactivation of Hepatic EPO Synthesis in Mice After PHD Loss
2010 StandoutScienceNobel
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
1999 StandoutScienceNobel
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
1996 StandoutNobel
Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
1998
Coexpression of Erythropoietin and Vascular Endothelial Growth Factor in Nervous System Tumors Associated With von Hippel-Lindau Tumor Suppressor Gene Loss of Function
1998
A second major native von Hippel–Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor
1998
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling
2002 StandoutScienceNobel
VEGF Receptor Signal Transduction
2001
Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice
1998
von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
1998 StandoutNobel
The von Hippel-Lindau Tumor Suppressor Gene Product Interacts with Sp1 To Repress Vascular Endothelial Growth Factor Promoter Activity
1997
ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.
2000
Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels
1996
The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells
1999 StandoutNobel
Skeletal defects in VEGF120/120 mice reveal multiple roles for VEGF in skeletogenesis
2002
Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2
1998 StandoutNobel
Angiogenesis in Endocrine Tumors
2003
Signal relays in the VEGF system
1999
Structural Basis of Transcription: RNA Polymerase II at 2.8 Ångstrom Resolution
2001 StandoutScienceNobel
The splice variants of vascular endothelial growth factor (VEGF) and their receptors
2001
THE UBIQUITIN SYSTEM
1998 StandoutNobel
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Vascular endothelial growth factor (VEGF) and its receptors
1999 Standout
VEGF and flt
1996
Diverse Effects of Mutations in Exon II of the von Hippel-Lindau (VHL) Tumor Suppressor Gene on the Interaction of pVHL with the Cytosolic Chaperonin and pVHL-Dependent Ubiquitin Ligase Activity
2002 StandoutNobel
De novo design of protein logic gates
2020 StandoutScienceNobel
Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
1999 Standout
The Molecular Basis of Von Hippel-Lindau Disease
1997 StandoutNobel
Works of Bernhard Barleon being referenced
Mapping of the Sites for Ligand Binding and Receptor Dimerization at the Extracellular Domain of the Vascular Endothelial Growth Factor Receptor FLT-1
1997
Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 Cells
1995
Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells
1994
Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors
2001
Release and Complex Formation of Soluble VEGFR-1 from Endothelial Cells and Biological Fluids
2000
An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells
1998
Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
1996
Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells.
1997
Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy.
2001